Improved Immunotoxins with Novel Functional Elements

Author(s): C. Hetzel, C. Bachran, M K. Tur, H. Fuchs, M. Stocker

Journal Name: Current Pharmaceutical Design

Volume 15 , Issue 23 , 2009

Become EABM
Become Reviewer

Abstract:

Immunotoxins (ITs) are protein-based drugs combining a target-specific binding domain (usually derived from an antibody) and a cytotoxic domain to kill target cells. They are among the most promising new therapeutic tools to fight cancer, and several clinical trials have been completed with encouraging results. Although the targeted elimination of malignant cells is an elegant concept, there are numerous practical challenges that limit the clinical use of ITs, including inefficient cellular uptake, low cytotoxicity and off-target effects. Here we present some of the strategies that have been developed to improve the efficacy of ITs, particularly those involving the incorporation of functional peptide sequences into recombinant ITs to improve target binding, modify plasma half life and distribution, boost tumor penetration, enhance cellular uptake and increase cytotoxic efficiency.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 23
Year: 2009
Page: [2700 - 2711]
Pages: 12
DOI: 10.2174/138161209788923930
Price: $65

Article Metrics

PDF: 4